Document Detail

Synergistic Killing of Glioblastoma Stem-like Cells by Bortezomib and HDAC Inhibitors.
MedLine Citation:
PMID:  22753697     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge.
MATERIALS AND METHODS: Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines. Cell survival, proliferation and death were analyzed by fluorometric microculture cytotoxicity assay (FMCA), propidium iodide labeling and flow cytometry, and cell cloning through limiting dilution and live-cell bright-field microscopy.
RESULTS: Bortezomib and the HDAC inhibitors showed synergistic cell killing at clinically relevant drug concentrations, while the conventional cell lines cultured in serum-containing medium were relatively resistant to the same treatments.
CONCLUSION: These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs.
Thomas Asklund; Samuel Kvarnbrink; Camilla Holmlund; Carl Wibom; Tommy Bergenheim; Roger Henriksson; Håkan Hedman
Related Documents :
11180517 - Cytotoxic effects of plant extracts from the families fabaceae, oleaceae, philadelphace...
3504217 - Virulence associated ingestion of legionella pneumophila by hela cells.
6541657 - Microfilament organization and total actin content are decreased in hybrids derived fro...
8806687 - Pic 1, a novel ubiquitin-like protein which interacts with the pml component of a multi...
7589247 - Ricin toxicity and intracellular routing in tumoral ht-29 cells. i. ricin routing and t...
17884947 - Cellular defense mechanisms against benzo[a]pyrene in testicular leydig cells: implicat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  2407-13     Citation Subset:  IM    
Department of Radiation Sciences and Oncology, Umeå University, SE-90187, Umeå, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cel...
Next Document:  Effects of (5Z)-7-oxozeaenol on MDA-MB-231 breast cancer cells.